The Company's business model capitalizes on inventions and technology from which profits are created through licensing. MSI is dedicated to earning profit for its 8,600 shareholders by identifying, supporting, patenting and marketing technical innovation by harvesting top technology talent to bring game-changing product to the market.
We emphasize novel technology in the Nanomedicine space with the potential to be disruptive and the ability to establish sustainable businesses.
We are "patient capital" with experienced business building partners who bring the perspective of merchant bankers, not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune/1000 or larger). The entrepreneurial scientists and engineers who join us create personal success and wealth on an accelerated basis by virtue of ownership of publicly traded Manhattan Scientifics shares (OTC BB: MHTX).more...
April 9, 2013
Manhattan Scientifics Announces Receipt of $2.5M Commitment to Build Breakthrough Cancer Detection
NEW YORK--Manhattan Scientifics announced today that it has received the initial $1 million of a $2.5 million commitment to build the first generation of its advanced cancer detection devices.more...
April 3, 2013
Interview with mobile phone inventor Marty Cooper
The first mobile phone call was made 40 years ago today, on 3 April 1973. Martin Cooper, at the time a senior engineer at Motorola and now a member of our Science and Technology Committee, called a rival colleague at another telecoms company and announced he was speaking from "a 'real' cell telephone".more...
January 7, 2013
Cancer Research: NFCR Cites MHTX’s Early Cancer Detection Tech as Research Breakthrough for 2012
ALBUQUERQUE, N.M.--The National Foundation for Cancer Research (NFCR) has listed the SQUID-based cancer imaging technology developed by MHTX's (OTCBB: MHTX) Senior Scientific subsidiary as a "2012 Research Breakthrough."more...
August 28, 2012
Steven C. Miller Named Chief Commercialization Officer at Senior Scientific Subsidiary of MHTX
ALBUQUERQUE, N.M.--Manhattan Scientifics announced today that its Senior Scientific subsidiary has named Steven C. Miller, Ph.D. to the position of Chief Commercialization Officer.more...
August 13, 2012
MHTX Achieves Significant Milestones in Pursuit of its Early Cancer Detection & Treatment Technology
ALBUQUERQUE, N.M.--Manhattan Scientifics (OTCBB:MHTX) announced today that it has achieved several critical milestones in the development of its proprietary technology for the early detection and treatment of cancer.more...
February 23, 2012
National Foundation For Cancer Research Funds Novel Approach To Early Detection Of Ovarian Cancer
ALBUQUERQUE, N.M.--The National Foundation for Cancer Research has awarded a grant to Dr. Robert C. Bast, Jr. of The University of Texas MD Anderson Cancer Center to work with Senior Scientific LLC, a company owned by Manhattan Scientifics (OTCBB: MHTX), to apply Senior Scientifics’ technology to the early detection of ovarian cancer.more...
December 19, 2011
Fortune: Manhattan Scientifics Is A Leader In The Race For A Better Mammogram
NEW YORK--"The race is on for a better mammogram" states the December 19th headline in Fortune Magazine's (online) story by Sierra Jiminez. The story then begins—and ends—with the breakthrough work of Edward R. Flynn, PhD, of Manhattan Scientifics Inc.more...
Manhattan Scientifics has acquired the exclusive rights to the key patents and IP and will soon be positioned to enter into manufacturing and licensing agreements.
Manhattan Scientifics and Senior Scientific, LLC have announced that they have begun cooperative work to commercialize Senior Scientific's nano medicine cancer detection technology.
Dr. Edward Flynn, founder and president of Senior Scientific, LLC, has developed a nanotechnology-based, magnetic imaging method for early diagnosis and treatment of cancer that could provide a significant increase in detection sensitivity.more...
Dr. Edward Flynn could save lives with a new, ground-breaking technology intended to detect cancer much earlier than current techniques can.